CONMED Corp: insider trades · United States · SEC (Form 4)

About CONMED Corp

CONMED Corp. (ticker: CNMD) is a U.S.-based medical technology company listed on the NYSE in the United States. Headquartered in Largo, Florida, CONMED has been part of the med-tech landscape since 1970, when Eugene Corasanti founded the business. Over time, the company grew from a small medical distribution operation into an international surgical-device supplier with a meaningful footprint across the United States and abroad. CONMED’s business is centered on devices and equipment used in surgical procedures. Its portfolio is typically grouped into two broad areas: single-use products and capital equipment. The company serves multiple clinical specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. In orthopedics, CONMED focuses on sports medicine and soft-tissue repair solutions, including implants, anchors, and fixation systems. In general surgery, it offers surgical energy, access, smoke evacuation, suction/irrigation, and other operating-room consumables. This mix gives the company exposure to recurring disposable demand while also supporting higher-value equipment sales. From a competitive standpoint, CONMED operates in a crowded and highly regulated market alongside large diversified med-tech groups and specialized niche players. Its strategic strengths include product innovation, a broad procedure-oriented offering, and a commercial model that combines internal development, acquisitions, and distribution relationships. The company’s market position is supported by its ability to address multiple surgical specialties with integrated solutions rather than relying on a single product category. Geographically, CONMED is anchored by its corporate headquarters in Largo, Florida, and operates additional facilities in the United States, together with international locations that support sales and customer service in foreign markets. That footprint helps the company diversify its revenue base beyond the domestic market. Recent developments have included the release of full-year 2025 results in January 2026, where management highlighted revenue growth as well as operational optimization efforts, product rationalization, and European regulatory compliance work. CONMED also disclosed an updated share repurchase program in late 2025, suggesting a more active capital-allocation stance. For investors, CONMED remains a U.S.-listed healthcare name whose performance depends on surgical procedure volumes, product innovation, execution in manufacturing and supply chain, and adherence to an increasingly demanding regulatory environment.